Marijuana use motives: concurrent relations to frequency of past 30-day use and anxiety sensitivity among young adult marijuana smokers

Addictive Behaviors
Marcel O Bonn-MillerAmit Bernstein

Abstract

The present investigation examined two theoretically relevant aspects of marijuana motives using the Marijuana Motives Measure (MMM) [Simons, J., Correia, C. J., Carey, K. B., & Borsari, B. E. (1998). Validating a five-factor marijuana motives measure: Relations with use, problems, and alcohol motives. Journal of Counseling Psychology 45, 265-273] among 141 (78 female) young adults (M(age)=20.17, S.D.=3.34). The first objective was to evaluate the incremental validity of marijuana motives in relation to frequency of past 30-day use after controlling for the theoretically relevant factors of the number of years using marijuana (lifetime), current levels of alcohol, as well as tobacco smoking use. As expected, coping, enhancement, social, and expansion motives each were uniquely and significantly associated with past 30-day marijuana use over and above the covariates; conformity motives were not a significant predictor. A second aim was to explore whether coping, but no other marijuana motive, was related to the emotional vulnerability individual difference factor of anxiety sensitivity (fear of anxiety). As hypothesized, after controlling for number of years using marijuana (lifetime), past 30-day marijuana use, current levels o...Continue Reading

References

May 1, 1991·Journal of Personality and Social Psychology·J H BlockJ H Block
Jan 1, 1986·Behaviour Research and Therapy·S ReissR J McNally
Nov 1, 1971·The British Journal of Addiction to Alcohol and Other Drugs·E N Gale, G Guenther
Jan 1, 1995·Journal of Drug Education·C E Werch, D Anzalone
Dec 7, 1994·JAMA : the Journal of the American Medical Association·H WechslerS Castillo
Jun 11, 1998·Alcoholism, Clinical and Experimental Research·P J ConrodJ Vassileva
Feb 28, 2002·Journal of Abnormal Psychology·Richard A BrownDavid R Strong
Nov 5, 2002·Journal of Clinical Pharmacology·Alan J Budney, Brent A Moore
Aug 29, 2003·Journal of Abnormal Psychology·Alan J BudneyJohn R Hughes
Mar 3, 2004·Journal of Abnormal Psychology·Paul E Meehl
May 12, 2004·Addictive Behaviors·Michael J ZvolenskyRichard A Brown
Jun 2, 2005·Journal of Anxiety Disorders·Michael J ZvolenskyChristopher W Kahler
Jul 12, 2005·Behaviour Research and Therapy·Amit BernsteinEllen W Leen-Feldner
Dec 6, 2005·Journal of Anxiety Disorders·Amit BernsteinNorman B Schmidt

❮ Previous
Next ❯

Citations

Jun 29, 2011·Psychopharmacology·Aimee L McRae-ClarkKathleen T Brady
Apr 9, 2013·Psychopharmacology·Aimee L McRae-ClarkKathleen T Brady
Jan 17, 2012·Clinical Psychology Review·Danielle E RamoJudith J Prochaska
Nov 3, 2010·Cognitive Behaviour Therapy·Julianna HoganMichael J Zvolensky
Feb 22, 2011·Cognitive Behaviour Therapy·Marcel O Bonn-MillerJames J Gross
Oct 12, 2011·Sports Medicine·Marilyn A HuestisOlivier Rabin
Oct 12, 2012·Journal of Behavioral Medicine·Marcel O Bonn-MillerJodie A Trafton
Nov 15, 2011·The Behavioral and Brain Sciences·Christian P Müller, Gunter Schumann
Jun 16, 2014·Addictive Behaviors·Mallory Loflin, Mitch Earleywine
Aug 20, 2010·Journal of Women's Health·Marcel A de DiosMichael Stein
Jun 23, 2012·AJOB Neuroscience·Hanna Pickard
Aug 30, 2008·Substance Use & Misuse·Marcel O Bonn-MillerMichael J Zvolensky
Feb 28, 2016·Addictive Behaviors·Stephen SemchoEllen W Leen-Feldner
Jun 27, 2015·The American Journal of Drug and Alcohol Abuse·Joseph J PalamarDimitra Kamboukos
Aug 4, 2015·Developmental Cognitive Neuroscience·Skyler G ShollenbargerKrista Lisdahl
Sep 24, 2011·Journal of Substance Abuse Treatment·Marcel A de DiosMichael D Stein
Nov 18, 2015·Psychiatry Research·Emilie SchmitsEtienne Quertemont
Nov 14, 2008·Journal of Substance Abuse Treatment·Scott M Hyman, Rajita Sinha
Dec 5, 2015·Depression and Anxiety·Ethan MoitraMichael D Stein
May 5, 2007·Addictive Behaviors·Julia D BucknerNorman B Schmidt
Jan 24, 2007·Addictive Behaviors·Marcel O Bonn-MillerAmit Bernstein
Aug 21, 2009·Human Psychopharmacology·José Alexandre CrippaPaolo Fusar-Poli
Aug 28, 2007·Journal of Traumatic Stress·Marcel O Bonn-MillerMichael J Zvolensky
Mar 31, 2011·Depression and Anxiety·Julia D BucknerNorman B Schmidt
Dec 10, 2013·The American Journal on Addictions·Melissa M NorbergMichael J Zvolensky
Jul 14, 2010·Addictive Behaviors·Jumi HayakiMichael D Stein
May 2, 2015·Philosophy and Phenomenological Research·Hanna Pickard
Oct 16, 2015·Addictive Disorders & Their Treatment·Dawn W FosterMichael J Zvolensky
Nov 12, 2013·The American Journal of Drug and Alcohol Abuse·Marcel O Bonn-MillerKimberly A Babson
Nov 15, 2014·Substance Use & Misuse·Kristen G AndersonHelene R White
Apr 25, 2009·Substance Abuse Treatment, Prevention, and Policy·Joan L BottorffTamsin Mulvogue
Dec 11, 2013·Addictive Behaviors·Claire E BlevinsRoger A Roffman
Apr 2, 2014·Drug and Alcohol Dependence·Kelsey E BanesRoger A Roffman
Apr 26, 2016·The American Journal of Drug and Alcohol Abuse·Claire E BlevinsRobert S Stephens
Aug 31, 2016·Addictive Behaviors·R Kathryn McHughRoger D Weiss
Sep 1, 2016·Drug and Alcohol Dependence·Claire E BlevinsRoger A Roffman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.